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Purpose: Recent studies have shown that decorin gene therapy inhibits neovascularization in 
many non-ocular tissues. We tested the efficacy of decorin gene delivery into stroma with AAV5 
to impede vascular endothelial growth factor (VEGF)-induced angiogenesis in rabbit cornea in 
vivo.
Methods: New zealand White rabbits were used in our study. Corneal neovascularization was 
induced by implanting a sucralfate-hydron pellet containing 650ng VEGF using micropocket 
assay. Decorin gene delivery into rabbit stroma was accomplished via topical application of 
25µl AAV5 (5x10e9 vg/µl). Visual eye exam, stereomicroscopy, and slit-lamp microscopy were 
used to monitor corneal health. Changes in corneal neovascularization were measured with 
stereomicroscopy, immunocytochemistry, western blotting, and real-time PCR techniques. NIH 
Image J 1.38X and Adobe Photoshop software were used to quantify vasculature.
Results: AAV5 decorin gene delivery into stroma demonstrated a substantial reduction in 
blood vessel area compared to control corneas in a time-dependent fashion from day-3 to 
day-14. Stereo- and slit-lamp microscopy detected a considerable attenuation in corneal 
neovascularization (9.8-37.3%) in rabbit eyes in vivo with decorin gene therapy. The largest 
decrease in corneal angiogenesis was observed on day-10 (up to 37.3%). In addition, decorin-
overexpressing rabbit corneas exhibited delayed blood vessel appearance, thinning, and retarded 
migration towards the cornea compared to control. Preliminary immunochemistry, western 
blotting, and real-time PCR data support these observations. Clinical eye examination did not 
reveal any significant inflammation in test or control corneas. 
Conclusions: Decorin gene therapy effectively reduces corneal neovascularization in vivo. 
Studies are underway to delineate safety, toxicity, and doses of tested vectors.
